By Fineline Cube 
China-based JW Therapeutics (HKG: 2126), co-founded by Juno Therapeutics Inc. (a Bristol-Myers Squibb company) and WuXi AppTec in 2016, announced a technology licensing agreement with Juno. Upon approval from independent shareholders, JW Therapeutics will grant Juno a nonexclusive license to its JW sLVV production process and related technical knowledge. In return, Juno will pay JW Therapeutics up to USD 10 million.
Agreement Details
The licensing agreement allows Juno to access JW Therapeutics’ innovative sLVV production process, enhancing Juno’s capabilities in the field of gene therapy. This nonexclusive arrangement supports collaborative innovation and technological advancement in therapeutic development.-Fineline Info & Tech